Free Trial

TScan Therapeutics (TCRX) Insider Trading & Ownership

TScan Therapeutics logo
$4.64 +0.12 (+2.65%)
(As of 11/26/2024 ET)

TScan Therapeutics (NASDAQ:TCRX) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
2.76%
Number Of
Insiders Buying
(Last 12 Months)
3
Amount Of
Insider Buying
(Last 12 Months)
$253,038.68
Number Of
Insiders Selling
(Last 12 Months)
1
Amount Of
Insider Selling
(Last 12 Months)
$951,885.08
Get TCRX Insider Trade Alerts

Want to know when executives and insiders are buying or selling TScan Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

TCRX Insider Buying and Selling by Quarter

TScan Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2024Lynx1 Capital Management LpMajor ShareholderBuy947$4.34$4,109.98  
9/23/2024Barbara KlenckeDirectorBuy5,000$5.29$26,450.00  
8/26/2024Barbara KlenckeDirectorBuy5,000$5.53$27,650.00  
8/23/2024Barbara KlenckeDirectorBuy5,000$5.69$28,450.00  
8/23/2024Zoran ZdraveskiInsiderSell164,686$5.78$951,885.08  
12/18/2023Timothy J BarberichDirectorBuy28,830$4.89$140,978.70  
12/14/2023Barbara KlenckeDirectorBuy5,000$5.08$25,400.00  
(Data available from 1/1/2013 forward)

TCRX Insider Trading Activity - Frequently Asked Questions

The list of insiders at TScan Therapeutics includes Barbara Klencke, Brian M Silver, David P Southwell, Lynx1 Capital Management Lp, Timothy J Barberich, and Zoran Zdraveski. Learn more on insiders at TCRX.

2.76% of TScan Therapeutics stock is owned by insiders. Learn more on TCRX's insider holdings.

The following insiders have purchased TCRX shares in the last 24 months: Barbara Klencke ($107,950.00), Brian M Silver ($4,263.00), Lynx1 Capital Management Lp ($4,109.98), and Timothy J Barberich ($240,603.10).

Insiders have purchased a total of 90,499 TCRX shares in the last 24 months for a total of $356,926.08 bought.

The following insiders have sold TCRX shares in the last 24 months: Lynx1 Capital Management Lp ($64,008.00), and Zoran Zdraveski ($951,885.08).

Insiders have sold a total of 190,086 TScan Therapeutics shares in the last 24 months for a total of $1,015,893.08 sold.

TScan Therapeutics Key Executives

  • Dr. Gavin MacBeath Ph.D. (Age 54)
    CEO & Director
    Compensation: $650.17k
  • Dr. Stephen J. Elledge Ph.D.
    Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Tomasz Kula Ph.D.
    Co-Founder & Member of Advisory Board
  • Mr. Jason A. Amello (Age 56)
    Chief Financial Officer
  • Mr. Leiden Dworak M.B.A.
    Principal Accounting Officer & Treasurer
  • Dr. Justin McCue Ph.D.
    Chief Technology Officer
  • Ms. Ann Hargraves
    Senior Vice President of Human Resources
  • Dr. Shrikanta Chattopadhyay M.D.
    Senior VP & Head of Translational Medicine


This page (NASDAQ:TCRX) was last updated on 11/27/2024 by MarketBeat.com Staff
From Our Partners